Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells - Publikacja - MOST Wiedzy

Twoje konto

zaloguj

Wyszukiwarka

Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells

Abstrakt

Androgen receptor (AR) plays a crutial role in prostate cancer (PCa) development and metastasis. Here, we reported potent anti-PCa activity of a small molecule imidazoacridinone C-1311. In AR-positive PCa cells, C-1311 was found to inhibit the transcriptional activity of AR uncovering a novel mechanism that may be relevant for its anticancer effect. Mechanistically, C-1311 decreased AR binding to prostate-specific antigen (PSA) promoter, reduced PSA protein level, and as shown by transcriptome sequenvcing, down-regulated numerous AR target genes. Importantly, AR-negative PCa cells were also sensitive to C-1311, suggesting a promising efficacy in androgen-independent PCa sub-type. Irrespective of AR status, C-1311 induced DNA damage, arrested cell cycle progression and induced apoptosis. RNA sequencing indicated on the significant differences in transcriptional response to C-1311 between PCa cells. Gene ontology analysis showed that in AR-dependent PCa cells, C-1311 mainly affected DNA damage response pathways. In contrast, in AR-independent PCa cells, C-1311 targeted cellular metabolism and inhibited gene regulating glycolysis and gluconeogenesis. Together, these results indicate that C-1311 warrants further development for the treatment of PCa.

Cytowania

  • 4

    CrossRef

  • 0

    Web of Science

  • 5

    Scopus

Autorzy (11)

Cytuj jako

Pełna treść

pobierz publikację
pobrano 78 razy
Wersja publikacji
Accepted albo Published Version
Licencja
Creative Commons: CC-BY otwiera się w nowej karcie

Słowa kluczowe

Informacje szczegółowe

Kategoria:
Publikacja w czasopiśmie
Typ:
artykuły w czasopismach
Opublikowano w:
Biomedicines nr 8,
ISSN: 2227-9059
Język:
angielski
Rok wydania:
2020
Opis bibliograficzny:
Niemira M., Borowa-Mazgaj B., Bader S., Moszyńska A., Ratajewski M., Karaś K., Kwaśniewski M., Krętowski A., Mazerska Z., Hammond E., Skwarska A.: Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells// Biomedicines -Vol. 8,iss. 9 (2020), s.292-
DOI:
Cyfrowy identyfikator dokumentu elektronicznego (otwiera się w nowej karcie) 10.3390/biomedicines8090292
Weryfikacja:
Politechnika Gdańska

wyświetlono 144 razy

Publikacje, które mogą cię zainteresować

Transcriptomic Effects of Estrogen Starvation and Induction in the MCF7 Cells. The Meta-analysis of Microarray Results

2015

In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot−β−cyclodextrin carrier for C-2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers

2024

Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer

  • K. Tadi,
  • B. T. Ashok,
  • Y. Chen
  • + 5 autorów
2008

Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis

2011
Meta Tagi